Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Earnings

Cresco Labs Delivers Q4 2025 Revenue of $162 Million and Sequential Margin Improvement

By The Northwire Desk — AI Analysis Mar 05, 2026 · 06:30 CL · 1.33 Cresco Labs Inc.
CL · Price

Executive Summary

  • Cresc​o Labs reported FY 2025 revenue of $656 million, adjusted gross margin of 50.2% and Adjusted EBITDA of $157 million (24.0% margin).
  • The company posted a net loss of $140 million for the year, driven by one‑time non‑cash impairment charges of $105 million related to its New York and California reporting units.
  • Q4 2025 revenue was $162 million with Adjusted EBITDA of $40 million (25.0% margin) and operating cash flow of $27 million; net loss for the quarter was $89 million, again reflecting a $93 million impairment charge.

Key Details

  • Revenue: FY 2025 – $656 M; Q4 2025 – $162 M (down 2% YoY).
  • Gross Profit / Adjusted Gross Profit: FY 2025 – $325 M / $329 M; Adjusted gross margin – 50.2%.
  • Operating Cash Flow: FY 2025 – $73 M; Q4 2025 – $27 M.
  • Free Cash Flow (Non‑GAAP): FY 2025 – $38 M; Q4 2025 – $18 M.
  • Adjusted EBITDA: FY 2025 – $157 M (24.0% margin); Q4 2025 – $40 M (25.0% margin).
  • Net Loss: FY 2025 – $140 M; Q4 2025 – $89 M.
  • Impairment Charges: FY 2025 – $105 M (NY unit write‑down, CA fair‑value adjustments); Q4 2025 – $93 M (NY unit).
  • SG&A Expenses: FY 2025 – $218 M; Adjusted SG&A reduced 5.7% YoY to $200 M (30.4% of revenue).
  • Balance Sheet (12/31/2025): Cash & cash equivalents $91 M; Senior secured term loan debt $311 M; Mortgage loan $19 M; Total assets $1.197 B; Shareholders’ equity $252 M.
  • Share Count: 491,585,556 fully‑converted subordinate voting shares (as of 12/31/2025).
  • Conference Call: Scheduled for Thursday, March 5 2026 at 8:30 a.m. ET; webcast access details provided.

Notable Quotes

  • “In Q4, we strengthened our financial foundation while expanding margins and generating meaningful cashflow… Our focused strategy continues to enhance our competitive position.” – Management
  • “The cannabis industry is consolidating in real time… We are intentionally building a productive cash‑generating platform, balancing organic expansion with selective, accretive acquisitions…” – Management

All figures are presented in thousands of U.S. dollars unless otherwise noted.

Read the original news release →

More from Cresco Labs Inc.

Jun 08, 2026 · 06:00

Cresco Labs Closes US$50 Million Revolving Credit Facility with Needham Bank

Financings May 27, 2026 · 06:30

DEA Registration Puts Federal Imprimatur on Cresco’s Medical Operations, but Texas Setback Clouds Growth Ambitions

Regulatory May 11, 2026 · 06:30

Texas Regulator Pulls Back Cresco’s Conditional License, Clouding a Key Growth Catalyst

Regulatory May 08, 2026 · 06:30

Cresco Labs Q1 Earnings Show Revenue Stagnation Despite Regulatory Tailwinds and Texas License Award

Earnings Apr 23, 2026 · 13:24

Federal Rescheduling Validates Business Model, But Debt Overhang Remains Key Risk

Regulatory Apr 02, 2026 · 19:21

Cresco Labs receives Texas medical cannabis licence

Other